Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1264 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | Suspended. Referred 22/07/2016 |
| 16 September 2019 | The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 17 October 2018 - 14 November 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 July 2016 | Referral |
| 22 July 2016 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual